Brief: Kintara Therapeutics Requests Nasdaq For Additional 180-Day Extension To Regain Compliance With Minimum Bid Price Requirement
13/06/2024 23:26
June 13 (Reuters) - Kintara Therapeutics Inc KTRA.O :
* KINTARA THERAPEUTICS:ON JUNE 4,CO SUBMITTED REQUEST TO
NASDAQ
FOR ADDITIONAL 180-DAY EXTENSION TO REGAIN COMPLIANCE WITH
MINIMUM BID PRICE REQUIREMENT
* KINTARA THERAPEUTICS INC - RECEIVED A LETTER FROM NASDAQ
ADVISING THAT COMPANY HAD BEEN GRANTED A 180-DAY EXTENSION TO
DECEMBER 9
Source text for Eikon: ID:n0000950170-24-072991
Further company coverage: KTRA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on TuHURA Biosciences
See all newsBrief: Tuhura Biosciences Receives Key U.S. Patent For Its Groundbreaking Delta Opioid Receptor Antibody Drug Conjugate Technology
TuHURA Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update
TuHURA Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Tuhura Biosciences Inc Enters At The Market Offering Agreement With H.C. Wainwright & Co.